PDCD1 and non-small cell lung carcinoma: Programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors are examples of monoclonal antibodies commonly used in cancer immunotherapy, particularly in advanced NSCLC [77,78,79].